DPA, the third omega-3: what the evidence actually shows

Docosapentaenoic acid is a 22-carbon omega-3 with five double bonds — 22:5n-3. Structurally it is the missing link between its two famous siblings: EPA has 20 carbons and five double bonds (20:5n-3), DHA has 22 carbons and six (22:6n-3). DPA sits between them in the elongation and desaturation pathway that turns EPA into DHA, which is exactly why it is so easy to overlook — it is an intermediate, and intermediates rarely get their own supplement aisle.^[3][4]

That neglect is odd, because in human blood DPA is often more abundant than EPA. Despite this, the standard Omega-3 Index — the biomarker most clinics use to judge omega-3 status — counts EPA and DHA only, so DPA is invisible on most reports.^[2][3] If you want the wider picture of how the three differ in role and evidence, our companion piece on EPA, DHA and DPA lays them out side by side.

The first study to give humans pure DPA was small but informative: a randomized crossover design in which participants took 8 g/day of DPA for seven days. Plasma DPA rose, as expected. What made the result interesting is that EPA rose too — evidence of retroconversion, the body shortening DPA back to EPA — and DHA rose as well, through elongation. In the triacylglycerol fraction, all three long-chain omega-3s increased after giving only one of them.^[4]

That is the clearest human demonstration of DPA behaving as a reservoir: a pool the body can draw from in either direction depending on what it needs. It is a tidy story, and it is worth keeping honest. Isotope-tracer work using compound-specific analysis suggests retroconversion is a real but minor net contributor to circulating EPA, not a wholesale substitution.^[8] DPA is a flexible intermediate, not an interchangeable one.

The landmark dataset is the Pooling Project of 19 Cohort Studies, published in JAMA Internal Medicine in 2016. It harmonised individual-level biomarker data from 45,637 people and captured 7,973 total coronary heart disease events, including 2,781 fatal ones. Because it used measured blood levels rather than dietary recall, it sidesteps much of the noise that plagues nutrition epidemiology.^[1]

Per 1-standard-deviation higher blood level, the relative risks for fatal CHD were 0.94 for EPA (not statistically significant), 0.90 for DPA (95% CI 0.85–0.96) and 0.90 for DHA (0.84–0.96). For total CHD they were 0.94 for EPA (0.87–1.02), 0.94 for DPA (0.90–0.99) and 0.95 for DHA (0.91–1.00). Read those confidence intervals carefully and one point stands out: DPA was the only marine omega-3 significantly associated with lower total CHD.^[1]

A 2024 pooled analysis of 36 observational studies of circulating omega-3s and coronary heart disease reached broadly consistent conclusions, which is reassuring — the signal is not an artefact of one pooling exercise.^[9] None of this, it should be said, is randomised evidence. These are biomarker associations, and a biomarker can mark a healthier diet, a healthier person, or a causal pathway.

The FORCE consortium ran the same style of analysis for death from any cause, pooling 17 prospective cohorts — roughly 42,000 people, about 15,700 deaths, and a median follow-up of 16 years. Comparing the highest to the lowest quintile of blood levels, higher DPA was associated with roughly 15–18% lower risk of dying, sitting alongside EPA and DHA rather than behind them.^[2]

Earlier work pointed the same way. In the Cardiovascular Health Study, plasma phospholipid DPA in older adults was associated with lower total mortality, with the strongest single signal in that cohort coming from DHA for coronary death and DPA for stroke death.^[7] Across independent cohorts, in different populations, measured a decade apart, the DPA association keeps reappearing. That consistency is the strongest argument for taking it seriously.

Mechanistically, the most interesting property of DPA is that it is a substrate for specialized pro-resolving mediators — the resolvins, protectins and maresins that actively switch inflammation off rather than merely blocking it. DPA-derived mediators have been characterised largely in cell and animal models so far, so this is a promising mechanism rather than a demonstrated clinical effect.^[4]

Human biomarker data are more modest but point the same direction. In healthy adults, red-blood-cell DPA was inversely associated with both triglycerides and C-reactive protein, and rose dose-dependently with omega-3 supplementation.^[6] That is an association in a cross-sectional sample, not a treatment effect — but it is consistent with a fatty acid that participates in resolving inflammation rather than driving it.

Oily fish are the richest source — salmon, herring, mackerel and tuna all supply DPA, typically at around 10–20% of their EPA content. Then comes the fact that surprises most people: DPA is the main long-chain omega-3 in ruminant meat. Beef and lamb contain little EPA and almost no DHA, but they do contain DPA, which makes it the omega-3 that meat-eaters get most of.^[5][7]

Supplements are the weak link. Most fish-oil capsules contain only small amounts of DPA — on the order of 20–50 mg per gram of oil — because concentration processes are optimised for EPA and DHA. If you are comparing products, the krill-versus-fish-oil comparison covers how form and dose change what actually reaches your blood.

Here is the honest verdict. If you eat oily fish regularly, you are already getting DPA, and your body interconverts the three long-chain omega-3s to a useful degree. Standalone DPA supplements exist but are niche, expensive and barely studied in humans — the pivotal human dosing study involved a handful of participants over one week.^[4]

The evidence linking DPA to lower coronary risk and lower mortality is associative. Higher blood DPA tracks with better outcomes across many cohorts, which is a genuinely strong observational signal, but it does not establish that taking DPA in a capsule lowers anyone's risk. No randomised outcome trial of DPA exists.^[1][2]

So the fair conclusion is a modest one: DPA deserves far more research attention than it gets — and probably a place on the omega-3 panel your clinician orders — rather than a place at the top of a supplement stack. Eat the fish. Watch the science.